U.S. markets close in 6 hours 3 minutes
  • S&P 500

    4,153.37
    -35.06 (-0.84%)
     
  • Dow 30

    34,438.21
    -304.61 (-0.88%)
     
  • Nasdaq

    13,272.56
    -129.29 (-0.96%)
     
  • Russell 2000

    2,176.83
    -35.87 (-1.62%)
     
  • Crude Oil

    64.56
    -0.36 (-0.55%)
     
  • Gold

    1,825.20
    -12.40 (-0.67%)
     
  • Silver

    27.36
    -0.13 (-0.48%)
     
  • EUR/USD

    1.2176
    +0.0041 (+0.34%)
     
  • 10-Yr Bond

    1.6290
    +0.0270 (+1.69%)
     
  • GBP/USD

    1.4151
    +0.0029 (+0.21%)
     
  • USD/JPY

    108.5400
    -0.3010 (-0.28%)
     
  • BTC-USD

    55,607.75
    -1,989.97 (-3.45%)
     
  • CMC Crypto 200

    1,582.94
    +1,340.26 (+552.28%)
     
  • FTSE 100

    6,947.26
    -176.42 (-2.48%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Illumina, Inc. ILMN recently announced preliminary revenues for first-quarter 2021. The company expects to release detailed financial results for the period on Apr 27.

As per the preliminary report, first-quarter 2021 revenues are estimated to be approximately $1,085 million, up 26% from the year-ago quarter’s $859 million. The Zacks Consensus Estimate of $928.2 million remains below the preliminary figure.

As per the company, the sales uptick in the first quarter resulted from a surge in orders amounting to around $1.4 billion and year-over-year projected sequencing revenue growth of approximately 28%. Sequencing consumables business is expected to have grown by approximately 25% compared to the year-ago figures. Further, the preliminary estimate of COVID-19 surveillance revenues for sequencing consumables is approximately $20 million for the quarter.

Sequencing instrument business is expected to have registered growth of approximately 120% year over year, thus reflecting strength across all instrument categories.

Illumina now expects full-year 2021 revenue growth in the band of 25-28%, banking on the strength in its performance over the past few months. This is significantly up from its earlier projection of 17-20% announced in February. The Zacks Consensus Estimate for the full-year revenues is currently pegged at $3.89 billion.

Following this after-market release yesterday, shares of the company are up 10.1% in today’s premarket trading.

A Brief Q1 Analysis

Illumina, during the first quarter, observed a robust improvement in its Sequencing consumables arm compared to the pandemic phase, thus demonstrating strength in its core business. The company is upbeat about its performance in the to-be-reported quarter as the majority of its customers are now operating at pre-COVID-19 levels. Strength in its order receipts is also buoying optimism.

The company also confirmed in its preliminary results that its mid-throughput category recorded another solid quarter for placements. Per Illumina, some of its customers built additional capacity for COVID-19 surveillance work and accelerated instrument purchases. This resulted in approximately $35 million of incremental instrument revenues in the quarter.

Management also confirmed witnessing broad-based acceleration across Illumina’s core clinical and research applications with the increased adoption of next-generation sequencing (“NGS”). Additionally, the company recorded increased demand for COVID-19 surveillance, worldwide, due to the critical role that Illumina’s NGS technology plays to combat the pandemic.

Meanwhile, the company’s preliminary projection of a robust improvement in revenues compared to the sequentially last-reported quarter lifts our confidence.

Price Performance

Shares of the company have gained 0.6% in the past three months versus the industry’s 8.1% fall and the S&P 500’s 7.7% rise.

Zacks Rank & Key Picks

Currently, Illumina carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Hologic, Inc. HOLX, Hill-Rom Holdings, Inc. HRC and DENTSPLY SIRONA Inc. XRAY.

Hologic’s long-term earnings growth rate is estimated at 15.4%. The company presently sports a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Hill-Rom’s long-term earnings growth rate is estimated at 7.3%. It currently carries a Zacks Rank #2.

DENTSPLY’s long-term earnings growth rate is estimated at 20%. The company presently carries a Zacks Rank #2.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2021 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report

Hologic, Inc. (HOLX) : Free Stock Analysis Report

HillRom Holdings, Inc. (HRC) : Free Stock Analysis Report

To read this article on Zacks.com click here.